-
Bayer, Fosun, Zejing...Who is competing for the first-line targeted therapy market for liver cancer?
Time of Update: 2021-07-16
With the continuous increase in patients with liver cancer and the ever-increasing improvement of China's medical insurance policies, the market size of liver cancer drugs will further expand in the future, and it is expected to exceed 40 billion yuan by 2022 .
-
China Resources Sanjiu's 2020 net profit of 1.6 billion President Qiu Huawei salary 3.78 million
Time of Update: 2021-07-16
" The state continues to encourage innovation and development, pharmaceutical companies continue to increase their investment in R&D and innovation, and the speed of launching innovative drugs and their inclusion in medical insurance has further accelerated .
7842 million yuan from the company, and Assistant President and CFO Liang Zheng received a total pre-tax remuneration of 2.
-
Asia-Pacific Pharmaceutical: The judicial sale of 27 million shares held by Asia-Pacific Group and Asia-Pacific Real Estate has been suspended
Time of Update: 2021-07-16
Yuecheng District People’s Court of Shaoxing City, Zhejiang Province from 10:00 on March 7, 2021 to 10:00 on May 5, 2021 (except for the bidding cycle and delay) at the People’s Court of Yuecheng District, Shaoxing City, Zhejiang Province on Taobao Judicial Auction Network The 11 million shares of Asia Pacific Pharmaceuticals held by Asia Pacific Group and 16 million shares of Asia Pacific Pharmaceuticals held by Asia Pacific Real Estate are publicly sold on the platform .
-
Hua Medicine Announces 2020 Annual Results
Time of Update: 2021-07-16
During the reporting period, the company continued to promote various clinical trials and R&D investment, successfully completed two phase III registered clinical studies of dorzagliatin, and achieved outstanding results in promoting its commercialization process, which is the company’s future Long-term stable development has laid a solid foundation .
-
Gao Zhenkun, chairman of Beijing Tongrentang, resigns
Time of Update: 2021-07-16
issued an announcement that the board of directors received a written resignation from the chairman of the company, Mr.
Gao Zhenkun resigned from all positions of the company's directors and board of directors due to personal reasons .
-
Merck's PD-1 inhibitor Creida received approval for new dosage regimen in China
Time of Update: 2021-07-16
Li Zhengqing, Senior Vice President of Merck and President of China R&D Center, said: “Mercury is always committed to scientific exploration and seeking to bring innovative treatment and medication options to patients and medical workers .
-
Zhongchao Medical and GlaxoSmithKline renews contract to continue cooperation in the field of pulmonary hypertension
Time of Update: 2021-07-16
In 2021, the three parties will continue the project cooperation to provide a wider range of clinicians with a platform for knowledge update, skill learning and experience exchange in the field of pulmonary hypertension .
The success of the PAH project has provided us with valuable experience in carrying out rare disease education.
-
WuXi Biologics acquires Suqiao Biotech and enters into a strategic cooperation with Kangqiao Capital
Time of Update: 2021-07-16
" Suqiao Biologics Chairman, Kangqiao Capital Managing Director Jiang Mengjiao said, “As a leading global healthcare investment platform in Asia, we are very pleased to cooperate with WuXi Biologics to create greater value for Suqiao Biotech’s shareholders with its integrated capabilities and technology platform.
-
Osaikang: Subsidiary and Shanghai WuXi AppTec signed a cooperative development contract
Time of Update: 2021-07-16
According to the content of the agreement, in accordance with the requirements of the China National Medical Products Administration and relevant regulations, the preclinical candidate compound (PCC) and the preclinical candidate compound (PCC) of the first-class new drug development project for the treatment of Exon14 mutation and the third-generation EGFR inhibitor resistance of NSCLC Related research work on clinical candidate compounds (IND) .
-
China Resources Double Crane's 2020 net profit of 1.005 billion chronic disease business revenue declines
Time of Update: 2021-07-16
391 billion yuan, down 8% year-on-year, and net profit (attributable to the parent company) was 1.
151 million yuan, the total pre-tax remuneration received by the director and president Yu Shunting from the company was 2.
-
Boehringer Ingelheim, telmisartan oral solution for cats, Semile landed in China
Time of Update: 2021-07-16
Mi Music ® (Semintra ® , generic name: Cat with telmisartan oral solution) in the Chinese market, for the treatment of cats with chronic kidney disease caused by proteinuria .
-
Pfizer stops the sale of assets related to the production of biosimilar drugs in China
Time of Update: 2021-07-16
On March 17, Pfizer stated that it had decided to stop the production of biosimilar drugs in China and sold its Hangzhou-based biopharmaceutical production base to Wuxi Wuxi Biologics .
In addition, we understand that WuXi Biologics is also producing AstraZeneca vaccine raw materials for supply to Brazil .
-
The Sichuan Provincial Food and Drug Administration issued a notice to suspend the operation and use of the pharmaceutical compound honeysuckle granules in Lingyun County, Guangxi
Time of Update: 2021-07-16
On March 17, the Sichuan Provincial Drug Administration stated that it had recently received the Guangxi Zhuang Autonomous Region Drug Administration’s "Letter on Assisting the Recall of Compound Honeysuckle Granules from Guangxi Lingyun Pharmaceutical Co.
-
Ingram Medical benefited from the demand for anti-epidemic gloves, and its revenue increased by 564% last year
Time of Update: 2021-07-16
Ingram Medical focuses on the production and sales of personal protective equipment including disposable gloves .
Ingram Medical pointed out in its annual report that the epidemic caused a surge in demand for disposable gloves.
-
Deco Medical's world's first hydrogel implantation to treat heart failure succeeded in Xijing Hospital
Time of Update: 2021-07-16
The operation was performed by the team of Professor Tao Ling from the Department of Cardiovascular Medicine, Xijing Hospital, Air Force Military Medical University, and was used to treat a high-risk heart failure patient .
-
Genting Sunshine announces annual results for the year ended December 31, 2020
Time of Update: 2021-07-15
We continue to advance the development of drug candidates in major therapeutic areas, including the initiation of late-stage clinical trials of sacituzumab govitecan-hziy in two different breast cancer indications, which have a large number of unmet medical needs; we A phase 3 bridging trial was completed.
-
Johnson & Johnson Medical Joins Hands with Beijing Bethune Charity Foundation to Advocate Comprehensive Management of Heart and Brain Health
Time of Update: 2021-07-15
Participating experts and scholars advocated the promotion of the concept of comprehensive management of cardiovascular and cerebrovascular diseases, advocated early diagnosis and treatment of heart and brain diseases, and the establishment of a multi-level medical payment system to vigorously promote the development of the "Healthy China 2030" plan.
-
The world's first nasopharyngeal cancer immunotherapy drug-Tuoyi New Indications National Launch Conference held
Time of Update: 2021-07-15
Professor Xu Ruihua, the principal investigator of POLARIS-02, Dean of Sun Yat-sen University Cancer Center, congratulated on the launch of the new indication of Teriprizumab in his speech, and fully affirmed that Chinese researchers, researchers and patients are global nasopharyngeal Contributions to the development of cancer treatment .
-
Hebo Pharmaceutical's new-generation anti-CTLA-4 antibody phase I clinical trial in China completed the first patient administration
Time of Update: 2021-07-15
How to improve the effective rate of treatment through innovative solutions and further improve the survival of patients is currently an urgent problem to be solved .
-
Genting Xinyao Announces China National Medical Products Administration Accepts Xerava(TM) Drug Marketing Authorization Application for the Treatment of Adults with Complex Intra-abdominal Infections
Time of Update: 2021-07-15
Everest Medicines (Everest Medicines), a biopharmaceutical company focusing on the development and commercialization of innovative drugs, is committed to meeting the unmet medical needs in Greater China and other Asian markets.
XeravaTM (eravacycline, eravacycline) is used for the treatment of adult complicated intra-abdominal infection (cIAI) in China for the drug marketing authorization application .